Eiger BioPharmaceuticals Class Action Lawsuit EIGR | Deadline January 9, 2023

Announcement! Investors who bought Eiger BioPharmaceuticals, Inc. (EIGR) stocks between March 10, 2021, and October 4, 2022, have a legal claim in the EIGR class action lawsuit (Eiger BioPharmaceuticals Class Action Lawsuit).

CLICK HERE TO LEARN MORE ABOUT THE EIGR CLASS ACTION LAWSUIT.

The Eiger lawsuit alleges that the defendants made false and/or deceptive representations and/or failed to disclose the following throughout the Class Period:

(i) The experience of Eiger in clinical and regulatory drug development was exaggerated by the defendants;

(ii) defendants overlooked problems with the TOGETHER study’s design and its capacity to support the Emergency Use Authorization (“EUA”) for the Company’s product candidate, peginterferon lambda, or failed to adequately evaluate them;

(iii) There were problems with the TOGETHER study’s conduct, or the study wasn’t correctly planned for the peginterferon lambda EUA in the pandemic’s contemporary environment;

(iv) Consequently, the U.S. The Food and Drug Administration was not likely to accept the peginterferon lambda EUA submission;

(v) as a result, all of those mentioned above led to an overestimation of peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19; and

(vi) Therefore, at all material times, the Company’s public statements were materially false and misleading.

If you suffered a loss in Eiger you have until January 9, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.